{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T06:06:29Z","timestamp":1762927589846},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2002,10]]},"DOI":"10.1053\/shem.2002.36927","type":"journal-article","created":{"date-parts":[[2002,11,22]],"date-time":"2002-11-22T16:28:11Z","timestamp":1037982491000},"page":"32-37","source":"Crossref","is-referenced-by-count":24,"special_numbering":"S","title":["Targeted therapies in the treatment of Philadelphia chromosome\u2013positive acute lymphoblastic leukemia"],"prefix":"10.1053","volume":"39","author":[{"given":"Dieter","family":"Hoelzer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"G\u00f6kbuget","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver G","family":"Ottmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/shem.2002.36927_BIB1","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"issue":"suppl 3","key":"10.1053\/shem.2002.36927_BIB2","first-page":"6","article-title":"Evaluating the effect of P210 BCR\/ABL on growth of hematopoietic progenitor cells and its role in the pathogenesis of human chronic myelogenous leukemia","volume":"30","author":"Gishizky","year":"1993","journal-title":"Semin Hematol"},{"key":"10.1053\/shem.2002.36927_BIB3","first-page":"1391","article-title":"Clonal characteristics of acute lymphoblastic cells derived from BCR\/ABL p190 transgenic mice","volume":"7","author":"Griffiths","year":"1992","journal-title":"Oncogene"},{"key":"10.1053\/shem.2002.36927_BIB4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/344251a0","article-title":"Acute leukaemia in bcr\/abl transgenic mice","volume":"344","author":"Heisterkamp","year":"1990","journal-title":"Nature"},{"key":"10.1053\/shem.2002.36927_BIB5","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1073\/pnas.87.17.6649","article-title":"Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR\/ABL","volume":"87","author":"Kelliher","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/shem.2002.36927_BIB6","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1182\/blood.V86.12.4603.bloodjournal86124603","article-title":"BCR\/ABL P210 and P190 cause distinct leukemia in transgenic mice","volume":"86","author":"Voncken","year":"1995","journal-title":"Blood"},{"issue":"suppl 17","key":"10.1053\/shem.2002.36927_BIB7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1053\/sonc.2001.29184","article-title":"Imatinib mesylate: Clinical results in Philadelphia chromosome-positive leukemias","volume":"28","author":"Kantarjian","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1053\/shem.2002.36927_BIB8","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood.V99.5.1536","article-title":"Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: A prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis","volume":"99","author":"Glei\u00dfner","year":"2002","journal-title":"Blood"},{"key":"10.1053\/shem.2002.36927_BIB9","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res"},{"key":"10.1053\/shem.2002.36927_BIB10","first-page":"139","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1053\/shem.2002.36927_BIB11","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/shem.2002.36927_BIB12","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/shem.2002.36927_BIB13","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1053\/shem.2002.36927_BIB14","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.1053\/shem.2002.36927_BIB15","first-page":"540","article-title":"New approaches to acute lymphoblastic leukemia in adults: Where do we go?","volume":"27","author":"Hoelzer","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1053\/shem.2002.36927_BIB16","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase II study of imatinib mesylate (Glivec\u2122) in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias","volume":"100","author":"Ottmann","year":"2002","journal-title":"Blood"},{"key":"10.1053\/shem.2002.36927_BIB17","first-page":"18","article-title":"STI571 (Glivec) to enable allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"23","author":"Wassmann","year":"2001","journal-title":"Onkologie"},{"issue":"suppl 1","key":"10.1053\/shem.2002.36927_BIB18","first-page":"589a","article-title":"Activity of the ABL-tyrosine kinase inhibitor Glivec (STI571) in Philadelphia chromosome positive acute lymphoblastic leukemia (PH+ALL) relapsing after allogeneic stem cell transplantation (allo-SCT)","volume":"98","author":"Ottmann","year":"2001","journal-title":"Blood"},{"issue":"suppl 7","key":"10.1053\/shem.2002.36927_BIB19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0037-1963(01)90126-X","article-title":"Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies","volume":"38","author":"Karp","year":"2001","journal-title":"Semin Hematol"},{"key":"10.1053\/shem.2002.36927_BIB20","first-page":"232","article-title":"Quantitative Taqman PCR analysis of BCR-ABL levels in peripheral blood and bone marrow of Ph acute lymphoblastic leukemia (ALL) patients during treatment with STI571","volume":"2","author":"Scheuring","year":"2001","journal-title":"Hematol J"},{"key":"10.1053\/shem.2002.36927_BIB21","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","article-title":"Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR\/ABL\u2013transformed hematopoietic cell lines","volume":"95","author":"Weisberg","year":"2000","journal-title":"Blood"},{"key":"10.1053\/shem.2002.36927_BIB22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","article-title":"BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study","volume":"359","author":"von Bubnoff","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/shem.2002.36927_BIB23","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1182\/blood.V99.5.1860","article-title":"Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation","volume":"99","author":"Hofmann","year":"2002","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196302500822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196302500822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T10:27:13Z","timestamp":1583922433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196302500822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["S0037196302500822"],"URL":"https:\/\/doi.org\/10.1053\/shem.2002.36927","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}